Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumour associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.
申请公布号
CA2227040(A1)
申请公布日期
1997.03.06
申请号
CA19962227040
申请日期
1996.08.13
申请人
ZENECA LIMITED
发明人
MARSHAM, PETER ROBERT;HENNAM, JOHN FREDERICK;DAVIES, DAVID HUW;HENNEQUIN, LAURENT FRANCOIS ANDRE;DOWELL, ROBERT IAN;BLAKEY, DAVID CHARLES;SLATER, ANTHONY MICHAEL